Sbir phase III - reversing immune dysregulation during spaceflight missions
Ended Definitive Contract Awarded Last action
- Contract number
- 80NSSC24CA006
- Awardee
-
Sachi Bioworks, Inc. UEI NTKPGKZLXPC1
- Awarding agency
-
Shared Services Center
National Aeronautics and Space Administration
- Obligated
- $2,234,767
Award facts
- Contract value 100% obligated
- $2,234,767.00 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- Set-aside
- Total Small Business
- Competition
- Full and Open Competition after exclusion of sources · 500 offers Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Superior, CO 80027, USA
- Research
- SBIR Program Phase III Action
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Exercise an Option | $520,125 | |
| Funding Only Action | $553,798 | |
| Funding Only Action | $380,422 | |
| Funding Only Action | $380,422 | |
| Original award | $400,000 |
About this award
This is a $2,234,767 Small Business Innovation Research (SBIR) Phase III contract awarded by a Civilian federal agency to Sachi Bioworks, Inc., a self-certified small disadvantaged business located in Erie, Colorado. The contract is for research related to "Reversing Immune Dysregulation During Spaceflight Missions" and is a Firm Fixed Price Definitive Contract. This Phase III contract builds upon previous SBIR Phase I and II awards to Sachi Bioworks totaling approximately $6,771,477, which focused on developing innovative drug discovery methods to address immune system challenges faced by astronauts during long-duration space travel. The contract has a period of performance through March 17, 2026. In addition to their SBIR awards, Sachi Bioworks has also received notable federal grant funding, including a $1,979,313 grant from the Defense Health Agency for developing a brain-penetrant RNA therapeutic for amyotrophic lateral sclerosis (ALS) treatment, and a $131,498 grant from the National Institute of Diabetes and Digestive and Kidney Diseases for developing nanoligomer-based therapeutics for inflammatory bowel disease.
Quick answers
Who was awarded contract 80NSSC24CA006?
80NSSC24CA006 was awarded to Sachi Bioworks, Inc. by Shared Services Center (National Aeronautics and Space Administration) on March 18, 2024.
How much is contract 80NSSC24CA006 worth?
The government has obligated $2,234,767 on 80NSSC24CA006.
Was contract 80NSSC24CA006 competed?
The extent of competition for 80NSSC24CA006 was full and open competition after exclusion of sources. The government received 500 offers. It was set aside: Total Small Business.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award